Table 3.

Reason for discontinuation of treatment with abaloparatide

	n (%)
Total enrolled (N = 162)
Patients completed the course of treatment	105 (64.8)
Patients who discontinued treatment	57 (35.2)
Reasons for treatment discontinuation (N = 57)
Financial reasons/copay	18 (31.2)
Poor tolerabilitya	13 (22.8)
Other, reason not included	12 (21.1)
Mandatory formulary switch to another treatment	5 (8.8)
Do not know	4 (7.0)
Patient experience of new conditions	3 (5.3)
Patient requested treatment change	2 (3.5)
Lack of treatment efficacy	2 (3.5)

^aAmong patients who discontinued abaloparatide due to poor tolerability, one patient each reported: chronic fatigue; developed itching; dizziness and heart palpitations; fatigue and generalized aching; fatigue, weakness, and memory issues; heart pounding/palpitations; heart racing; hypercalcemia; palpitations and intermittent nausea; patient did not feel well on abaloparatide; reported decreased mentation; ringing in ears; and severe gastrointestinal issues, nausea, and vomiting